

Models and Assays for Evaluating Anti-Emetic Potential as well as Emetic Activity

Our studies evaluating emetic liability and testing potentially anti-emetic agents have primarily used ferrets and *Suncus murinus* (musk shrew). More information about the use of these models is shown below, along with examples of relevant publications.

More recently recordings of the electrogastrogram using radiotelemetry in ferrets [34, 48] and *Suncus murinus* [50] as well as mice have been used. Together with these, recordings of gastric slow waves using tissue sections on a microelectrode array platform have been used [68, 70, 72] to provide a new *in vitro* paradigm for investigating gastrointestinal function and anti-emetic activity in disease models. See below for a further description of this new paradigm.



Ferrets: Whole Body Plethysmography Chamber

- noise suppressed design
- temperature and humidity control probes.
- sensitive pressure transducer that measures pressure changes inside the chamber through air flow regulation.



Using the ferret, studies have looked at the mechanism of several drugs that cause emesis including apomorphine [1, 29], morphine [1, 5, 10], ipecacuanha [1, 39, 64], copper sulphate [1, 5, 14], chemotherapeutic agents [1, 8, 9, 15, 26], prostanoids [21, 32, 41, 43], and a range of peptides (e.g. exendin-4) [59, 65]. Other ferret studies on 5-HT₃ and NK₁ receptor antagonists have examined the anti-emetic potential of cannabinoids [52], dopamine receptor antagonists [1, 15, 32], opioids [5], peptides (e.g. exendin (9-39), ghrelin) [33], prostanoid receptor antagonists (unpublished), glucocorticoids [19, 36], ACTH analogs [26], monoamine reuptake inhibitors [39] and pungent and non-pungent vanilloids [42, 49, 53, 63].

Using *Suncus murinus*, studies have investigated the emetic properties of prostanoids [23, 25], chemotherapy [24] and the mechanisms of motion-induced emesis [17, 50]. The anti-emetic mechanism of action of opioids [18], NK₁ tachykinin receptor antagonists [17, 30], 5-HT₃ receptor antagonists and glucocorticoids [24], vanilloids [20], antitussive drugs [37], and anti-histamines [66] and peptides including exendin-(9-39) [58], ghrelin [67, 69], and nesfatin [73] have also been investigated. This species has also been used to investigate mechanisms of drug- and chemotherapy-induced pica [27].

Techniques used in Emesis Research Projects


During experimentation, the following techniques/paradigms have been used:

- Examine pharmacology of drugs by oral, subcutaneous, intraperitoneal, intravenous, intraventricular, and intracerebral routes (see above for references)
- Define the potency of drugs on isolated tissues (e.g. ileum [35, 40])
- Evaluate drugs on mechanisms involved in the peristaltic reflex [31]
- Feeding experiments [57]
- Pica experiments [27]
- Microdialysis [45]
- Radiotelemetry [50]
- Measure glucose, insulin [55, 59]
- Use c-fos to investigate emetic pathways [58, 65]
- Investigate thermoregulation [60]
- Assess conditioned taste aversions [16]
- Lesion of abdominal vagi [23, 32, 41, 50]
- Lesion of the area postrema [44]
- Electrophysiological recordings from the isolated vagus nerve [28]
- Autoradiography [3-5]
- Heart rate variability studies [71]
- Assess cardiovascular function (radiotelemetry: BP, ECG,) [42, 53]
- Assess respiratory function (whole body plethysmography; [69, 72])

- Quantification of drug action on isolated tissues using the microelectrode array [38, 46, 47, 51, 54, 56]

A New Paradigm for Studying Gastric Dysfunction

Recording of electrical slow wave gastrointestinal pacemaker propagation activity has been used from isolated tissues for drug screening [68]. This proprietary protocol has been used to test >140 drugs on 4 types of tissues creating a novel Gastrointestinal Pacemaker Activity Drug Database (GIPADD). The current size of GIPADD allows >16 billion potential correlation tests to be calculated relative to clinical/preclinical data achieving 67-80% in predicting several drug adverse effects. The accuracy is expected to improve as new data sets are added. The unique slow wave electrical fingerprint of a new chemical entity is essentially matched to existing profiles in the database. This new approach to drug discovery is protected by a US patent. See <https://gutrhythmrhdhk.weebly.com> for additional information.



References

- Costall, B., A.M. Domeney, R.J. Naylor, J.B. Ower-Atepo, J.A. Rudd, and F.D. Tattersall (1990). Fluphenazine, ICS 205-930 and dl-fenfluramine

differentially antagonise drug-induced emesis in the ferret.

Neuropharmacology 29: 453-462.

2. Barnes, N.M., J. Ge, W.G. Jones, R.J. Naylor, and J.A. Rudd (1990).

Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine. *Br J Cancer* 62: 862-864.

3. Barnes, J.M., N.M. Barnes, B. Costall, I.L. Naylor, R.J. Naylor, and J.A.

Rudd (1990). Topographical distribution of 5-HT₃ receptor recognition sites in the ferret brain stem. *Naunyn Schmiedebergs Arch Pharmacol* 342: 17-21.

4. Barnes, J.M., N.M. Barnes, B. Costall, J.F. Deakin, J.W. Ironside, G.J. Kilpatrick, R.J. Naylor, J.A. Rudd, M.D. Simpson, P. Slater, and et al. (1990). Identification and distribution of 5-HT₃ recognition sites within the human brainstem. *Neurosci Lett* 111: 80-86.

5. Barnes, N.M., K.T. Bunce, R.J. Naylor, and J.A. Rudd (1991). The actions of fentanyl to inhibit drug-induced emesis. *Neuropharmacology* 30: 1073-1083.

6. Naylor, R.J. and J.A. Rudd (1992). Pharmacology of ondansetron. *Eur J Anaesthesiol Suppl* 6: 3-10.

7. Naylor, R.J. and J.A. Rudd (1994). Emesis and anti-emesis. *Cancer Surv* 21: 117-135.

8. Rudd, J.A., C.C. Jordan, and R.J. Naylor (1994). Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis. *Eur J Pharmacol* 262: R1-2.

9. Rudd, J.A. and R.J. Naylor (1994). Effects of 5-HT₃ receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. *Neuropharmacology* 33: 1607-1608.

10. Rudd, J.A. and R.J. Naylor (1995). Opioid receptor involvement in emesis and anti-emesis. In *Serotonin and the Scientific Basis of Anti-Emetic Therapy*. eds D.J.M. Reynolds, P.L.R. Andrews, and C.J. Davis Oxford Clinical Communications, Oxford, pp 208-219.

11. Rudd, J.A., C.C. Jordan, and R.J. Naylor (1996). The action of the NK₁ tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. *Br J Pharmacol* 119: 931-936.

12. Naylor, R.J. and J.A. Rudd (1996). Mechanisms of chemotherapy/radiotherapy-induced emesis in animal models. *Oncology* 53 Suppl 1: 8-17.

13. Rudd, J.A. and R.J. Naylor (1996). An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. *Br J Pharmacol* 118: 209-214.

14. Rudd, J.A., K.T. Bunce, and R.J. Naylor (1996). The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret. *Neuropharmacology* 35: 91-97.

15. Rudd, J.A., C.H. Cheng, and R.J. Naylor (1998). Serotonin-independent model of cisplatin-induced emesis in the ferret. *Jpn J Pharmacol* 78: 253-260.

16. Rudd, J.A., M.P. Ngan, and M.K. Wai (1998). 5-HT₃ receptors are not involved in conditioned taste aversions induced by 5-hydroxytryptamine, ipecacuanha or cisplatin. *Eur J Pharmacol* 352: 143-149.

17. Rudd, J.A., M.P. Ngan, and M.K. Wai (1999). Inhibition of emesis by tachykinin NK₁ receptor antagonists in *Suncus murinus* (house musk shrew). *Eur J Pharmacol* 366: 243-252.
18. Rudd, J.A., C.H. Cheng, R.J. Naylor, M.P. Ngan, and M.K. Wai (1999). Modulation of emesis by fentanyl and opioid receptor antagonists in *Suncus murinus* (house musk shrew). *Eur J Pharmacol* 374: 77-84.
19. Sam, T.S., S.W. Chan, J.A. Rudd, and J.H. Yeung (2001). Action of glucocorticoids to antagonise cisplatin-induced acute and delayed emesis in the ferret. *Eur J Pharmacol* 417: 231-237.
20. Rudd, J.A. and M.K. Wai (2001). Genital grooming and emesis induced by vanilloids in *Suncus murinus*, the house musk shrew. *Eur J Pharmacol* 422: 185-195.
21. Kan, K.K., R.L. Jones, M.P. Ngan, and J.A. Rudd (2002). Actions of prostanoids to induce emesis and defecation in the ferret. *Eur J Pharmacol* 453: 299-308.
22. Rudd, J.A., K. Yamamoto, A. Yamatodani, and N. Takeda (2002). Differential action of ondansetron and dexamethasone to modify cisplatin-induced acute and delayed kaolin consumption ("pica") in rats. *Eur J Pharmacol* 454: 47-52.
23. Kan, K.K., R.L. Jones, M.P. Ngan, J.A. Rudd, and M.K. Wai (2003). Emetic action of the prostanoid TP receptor agonist, U46619, in *Suncus murinus* (house musk shrew). *Eur J Pharmacol* 482: 297-304.
24. Sam, T.S., J.T. Cheng, K.D. Johnston, K.K. Kan, M.P. Ngan, J.A. Rudd, M.K. Wai, and J.H. Yeung (2003). Action of 5-HT₃ receptor antagonists and dexamethasone to modify cisplatin-induced emesis in *Suncus murinus* (house musk shrew). *Eur J Pharmacol* 472: 135-145.
25. Kan, K.K., R.L. Jones, M.P. Ngan, and J.A. Rudd (2003). Action of prostanoids on the emetic reflex of *Suncus murinus* (the house musk shrew). *Eur J Pharmacol* 477: 247-251.
26. Sam, T.S., K.K. Kan, M.P. Ngan, J.A. Rudd, and J.H. Yeung (2003). Action of metyrapone and tetracosactrin to modify cisplatin-induced acute and delayed emesis in the ferret. *Eur J Pharmacol* 466: 163-168.
27. Yamamoto, K., M.P. Ngan, N. Takeda, A. Yamatodani, and J.A. Rudd (2004). Differential activity of drugs to induce emesis and pica behavior in *Suncus murinus* (house musk shrew) and rats. *Physiol Behav* 83: 151-156.
28. Kan, K.K., R.L. Jones, M.P. Ngan, and J.A. Rudd (2004). Excitatory action of prostanoids on the ferret isolated vagus nerve preparation. *Eur J Pharmacol* 491: 37-41.
29. Lau, A.H., M.P. Ngan, J.A. Rudd, and D.T. Yew (2005). Differential action of domperidone to modify emesis and behaviour induced by apomorphine in the ferret. *Eur J Pharmacol* 516: 247-252.
30. Lau, A.H., J.A. Rudd, and D.T. Yew (2005). Action of ondansetron and CP-99,994 on cisplatin-induced emesis and locomotor activity in *Suncus murinus* (house musk shrew). *Behav Pharmacol* 16: 605-612.
31. Chan, S.K. and J.A. Rudd (2006). Role of bradykinin B2 receptors in the modulation of the peristaltic reflex of the guinea pig isolated ileum. *Eur J Pharmacol* 539: 108-115.

32. Kan, K.K., J.A. Rudd, and M.K. Wai (2006). Differential action of anti-emetic drugs on defecation and emesis induced by prostaglandin E2 in the ferret. *Eur J Pharmacol* 544: 153-159.
33. Rudd, J.A., M.P. Ngan, M.K. Wai, A.G. King, J. Witherington, P.L. Andrews, and G.J. Sanger (2006). Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. *Neurosci Lett* 392: 79-83.
34. Percie du Sert, N., J.A. Rudd, and P.L.R. Andrews (2007). Simultaneous telemetric recording of electrogastrogram (EGG) and emesis in the ferret. *Neurogastroenterol Motil* 19 (Suppl.3): 39.
35. Chan, S.W., J. He, G. Lin, J.A. Rudd, and K. Yamamoto (2007). Action of GLP-1 (7-36) amide and exendin-4 on *Suncus murinus* (house musk shrew) isolated ileum. *Eur J Pharmacol* 566: 185-191.
36. Sam, T.S., M.P. Ngan, D. Riendeau, A. Robichaud, and J.A. Rudd (2007). Action of cyclooxygenase inhibitors and a leukotriene biosynthesis inhibitor on cisplatin-induced acute and delayed emesis in the ferret. *J Pharmacol Sci* 103: 189-200.
37. Chan, S.W., J.A. Rudd, G. Lin, and P. Li (2007). Action of anti-tussive drugs on the emetic reflex of *Suncus murinus* (house musk shrew). *Eur J Pharmacol* 559: 196-201.
38. Yeung, C.K., J.K. Law, S.W. Sam, S. Ingebrandt, H.Y. Lau, J.A. Rudd, and M. Chan (2008). The use of microelectrode array (MEA) to study rat peritoneal mast cell activation. *J Pharmacol Sci* 107: 201-212.
39. Warneck, J.B., F.H. Cheng, M.J. Barnes, J.S. Mills, J.G. Montana, R.J. Naylor, M.P. Ngan, M.K. Wai, J.O. Daiss, R. Tacke, and J.A. Rudd (2008). Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret. *Toxicol Appl Pharmacol* 232: 369-375.
40. Cheng, F.H., S.W. Chan, and J.A. Rudd (2008). Contractile effect of tachykinins on *Suncus murinus* (house musk shrew) isolated ileum. *Neuropeptides* 42: 671-679.
41. Kan, K.K., M.P. Ngan, M.K. Wai, and J.A. Rudd (2008). Mechanism of the prostanoid TP receptor agonist U46619 for inducing emesis in the ferret. *Naunyn Schmiedeberg's Arch Pharmacol* 378: 655-661.
42. Rudd, J.A., K.M. Chu, M.K. Wai, and P.L.R. ANDrews (2008). Comparison of resiniferatoxin and olvanil on blood pressure, temperature and feeding in the ferret. *Canadian Journal of Clinical Pharmacology* 15: 638.
43. Kan, K.K.W. and J.A. Rudd (2008). Mechanism of sulprostone to induce emesis and defecation in the ferret. *Neurogastroenterol Motil* Submitted.
44. Percie du Sert, N., J.A. Rudd, R. Moss, and P.L. Andrews (2009). The delayed phase of cisplatin-induced emesis is mediated by the area postrema and not the abdominal visceral innervation in the ferret. *Neurosci Lett* 465: 16-20.
45. Yamamoto, K., S.W. Chan, J.A. Rudd, G. Lin, K. Asano, and A. Yamatodani (2009). Involvement of hypothalamic glutamate in cisplatin-induced emesis in *Suncus murinus* (house musk shrew). *J Pharmacol Sci* 109: 631-634.
46. Yeung, C.K., F. Sommerhage, G. Wrobel, J.K. Law, A. Offenhausser, J.A. Rudd, S. Ingebrandt, and M. Chan (2009). To establish a pharmacological

experimental platform for the study of cardiac hypoxia using the microelectrode array. *J Pharmacol Toxicol Methods* 59: 146-152.

47. Law, J.K., C.K. Yeung, B. Hofmann, S. Ingebrandt, J.A. Rudd, A. Offenhausser, and M. Chan (2009). The use of microelectrode array (MEA) to study the protective effects of potassium channel openers on metabolically compromised HL-1 cardiomyocytes. *Physiological measurement* 30: 155-167.

48. Percie du Sert, N., K.M. Chu, M.K. Wai, J.A. Rudd, and P.L. Andrews (2009). Reduced normogastric electrical activity associated with emesis: a telemetric study in ferrets. *World J Gastroenterol* 15: 6034-6043.

49. Chu, K.M., M.P. Ngan, M.K. Wai, C.K. Yeung, P.L. Andrews, N. Percie du Sert, and J.A. Rudd (2010). Olvanil: a non-pungent TRPV1 activator has anti-emetic properties in the ferret. *Neuropharmacology* 58: 383-391.

50. Percie du Sert, N., K.M. Chu, M.K. Wai, J.A. Rudd, and P.L. Andrews (2010). Telemetry in a motion-sickness model implicates the abdominal vagus in motion-induced gastric dysrhythmia. *Exp Physiol* 95: 768-773.

51. Law, J.K., C.K. Yeung, K.L. Yiu, J.A. Rudd, S. Ingebrandt, and M. Chan (2010). A study of the relationship between pharmacologic preconditioning and adenosine triphosphate-sensitive potassium (KATP) channels on cultured cardiomyocytes using the microelectrode array. *J Cardiovasc Pharmacol* 56: 60-68.

52. Percie du Sert, N., W.S. Ho, J.A. Rudd, and P.L. Andrews (2010). Cannabinoid-induced reduction in antral pacemaker frequency: a telemetric study in the ferret. *Neurogastroenterol Motil* 22: 1257-1266, e1324.

53. Chu, K.M., M.P. Ngan, M.K. Wai, C.K. Yeung, P.L. Andrews, N. Percie du Sert, G. Lin, and J.A. Rudd (2010). Olvanil, a non-pungent vanilloid enhances the gastrointestinal toxicity of cisplatin in the ferret. *Toxicol Lett* 192: 402-407.

54. Law, J.K., C.K. Yeung, S.P. Wan, S. Ingebrandt, H.Y. Lau, J.A. Rudd, and M. Chan (2011). The significance of chloride in the inhibitory action of disodium cromoglycate on immunologically-stimulated rat peritoneal mast cells. *Biochim Biophys Acta* 1810: 867-874.

55. Chan, S.W., G. Lin, D.T. Yew, and J.A. Rudd (2011). A physiological role of glucagon-like peptide-1 receptors in the central nervous system of *Suncus murinus* (house musk shrew). *Eur J Pharmacol* 668: 340-346.

56. Law, J.K., C.K. Yeung, L. Li, J.A. Rudd, S. Ingebrandt, and M. Chan (2012). The use of SU-8 topographically guided microelectrode array in measuring extracellular field potential propagation. *Ann Biomed Eng* 40: 619-627.

57. Chan, S.W., G. Lin, D.T. Yew, C.K. Yeung, and J.A. Rudd (2013). Separation of emetic and anorexic responses of exendin-4, a GLP-1 receptor agonist in *Suncus murinus* (house musk shrew). *Neuropharmacology* 70C: 141-147.

58. Chan, S.W., Z. Lu, G. Lin, D.T. Yew, C.K. Yeung, and J.A. Rudd (2014). The differential antiemetic properties of GLP-1 receptor antagonist, exendin (9-39) in *Suncus murinus* (house musk shrew). *Neuropharmacology* 83: 71-78.

59. Lu, Z., N. Percie Du Sert, S.W. Chan, C.K. Yeung, G. Lin, D.T. Yew, P.L. Andrews, and J.A. Rudd (2014). Differential hypoglycaemic, anorectic,

autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret. *J Transl Med* 12: 327.

60. Ngampramuan, S., M. Cerri, F. Del Vecchio, J.J. Corrigan, A. Kamphee, A.S. Dragic, J.A. Rudd, A.A. Romanovsky, and E. Nalivaiko (2014). Thermoregulatory correlates of nausea in rats and musk shrews. *Oncotarget* 5: 1565-1575.

61. Andrews, P.L.R. and J.A. Rudd (2015). The physiology and pharmacology of nausea and vomiting induced by anti-cancer chemotherapy in humans. In *Management of chemotherapy-induced nausea and vomiting: new agents and new uses of current agents*. ed R. Navari Springer Health Care Publishers: London, England.

62. Nalivaiko, E., J.A. Rudd, and R.H.Y. So (2015). Motion sickness, nausea and thermoregulation: the toxic hypothesis. *Temperature* 1: 164-171.

63. Rudd, J.A., E. Nalivaiko, N. Matsuki, C. Wan, and P.L. Andrews (2015). The involvement of TRPV1 in emesis and anti-emesis. *Temperature (Austin)* 2: 258-276.

64. Rudd, J.A., M.P. Ngan, Z. Lu, G.A. Higgins, C. Giuliano, E. Lovati, and C. Pietra (2016). Profile of Antiemetic Activity of Netupitant Alone or in Combination with Palonosetron and Dexamethasone in Ferrets and *Suncus murinus* (House Musk Shrew). *Front Pharmacol* 7: 263.

65. Lu, Z., C.K. Yeung, G. Lin, D.T.W. Yew, P.L.R. Andrews, and J.A. Rudd (2016). Insights into the central pathways involved in the emetic and behavioural responses to exendin-4 in the ferret. *Autonomic Neuroscience: Basic and Clinical* DOI: 10.1016/j.autneu.2016.09.003.

66. Tu, L., Z. Lu, K. Dieser, C. Schmitt, S.W. Chan, M.P. Ngan, P.L.R. Andrews, E. Nalivaiko, and J.A. Rudd (2017). Brain Activation by H1 Antihistamines Challenges Conventional View of Their Mechanism of Action in Motion Sickness: A Behavioral, c-Fos and Physiological Study in *Suncus murinus* (House Musk Shrew). *Front Physiol* 8: 412.

67. Rudd, J.A., S.W. Chan, M.P. Ngan, L. Tu, Z. Lu, C. Giuliano, E. Lovati, and C. Pietra (2018). Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT₃ Antagonist, Palonosetron and With the NK₁ Antagonist, Netupitant, Against Cisplatin- and Motion-Induced Emesis in *Suncus murinus* (House Musk Shrew). *Front Pharmacol* 9: 869.

68. Liu, J.Y.H., P. Du, W.Y. Chan, and J.A. Rudd (2019). Use of a microelectrode array to record extracellular pacemaker potentials from the gastrointestinal tracts of the ICR mouse and house musk shrew (*Suncus murinus*). *Cell Calcium* 80: 175-188.

69. Tu, L., Z. Lu, M.P. Ngan, F.F.Y. Lam, C. Giuliano, E. Lovati, C. Pietra, and J.A. Rudd (2019). The Brain-Penetrating Orally Active Ghrelin Receptor Agonist HM01 Ameliorates Motion-Induced Emesis in *Suncus murinus* (House Musk Shrew). *Br J Pharmacol* 177: 1635-1650.

70. Liu, J.Y.H., P. Du, and J.A. Rudd (2020). Acetylcholine exerts inhibitory and excitatory actions on mouse ileal pacemaker activity: role of muscarinic versus nicotinic receptors. *Am J Physiol Gastrointest Liver Physiol* 319: G97-G107.

71. Lu, Z., Y. Zhou, L. Tu, S.W. Chan, M.P. Ngan, D. Cui, Y.H.J. Liu, I.B. Huang, J.S.C. Kung, C.M.J. Hui, and J.A. Rudd (2020). Sulprostone-Induced Gastric Dysrhythmia in the Ferret: Conventional and Advanced Analytical Approaches. *Front Physiol* 11: 583082.
72. Tu, L., J.Y.H. Liu, Z. Lu, D. Cui, M.P. Ngan, P. Du, and J.A. Rudd (2021). Insights Into Acute and Delayed Cisplatin-Induced Emesis From a Microelectrode Array, Radiotelemetry and Whole-Body Plethysmography Study of *Suncus murinus* (House Musk Shrew). *Front Pharmacol* 12: 746053.
73. Lu, Z., D. Cui, J.Y.H. Liu, B. Jiang, M.P. Ngan, I. Sakata, S. Takemi, T. Sakai, G. Lin, S.W. Chan, and J.A. Rudd (2022). The Actions of Centrally Administered Nesfatin-1 on Emesis, Feeding, and Locomotor Activity in *Suncus murinus* (House Musk Shrew). *Front Pharmacol* 13: 858522.